Geron (GERN) Net Income towards Common Stockholders (2010 - 2026)
Geron's (GERN) quarterly Net Income towards Common Stockholders came in at -$3.6 million in Q1 2026, up 81.94% year-on-year from -$2.0 million in Q1 2025, and up 87.61% quarter-over-quarter from -$28.8 million in Q4 2025.
Geron (GERN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Geron has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$3.6 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$3.6 million, up 81.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$66.9 million (up 51.16% YoY), and the FY2025 annual result was -$83.1 million, up 51.85% from the prior year.
- Net Income towards Common Stockholders came in at -$3.6 million for Q1 2026 at Geron, up from -$28.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.6 million in Q1 2026 to a low of -$67.3 million in Q2 2024.
- The 5-year median for Net Income towards Common Stockholders is -$30.0 million (2022), against an average of -$34.5 million.
- Across the five-year window, Net Income towards Common Stockholders tumbled 68.39% in 2023 and jumped 81.94% in 2026, its largest moves.
- Geron's Net Income towards Common Stockholders stood at -$42.7 million in 2022, then retreated by 21.75% to -$52.0 million in 2023, then jumped by 54.63% to -$23.6 million in 2024, then declined by 22.02% to -$28.8 million in 2025, then jumped by 87.61% to -$3.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$3.6 million (Q1 2026), -$28.8 million (Q4 2025), and -$18.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Geron | 729,618.77 | 729,618.77 | - | -3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.57 Mn |
| Dec 31, 2025 | -28.79 Mn |
| Sep 30, 2025 | -18.27 Mn |
| Jun 30, 2025 | -16.31 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -23.60 Mn |
| Sep 30, 2024 | -26.38 Mn |
| Jun 30, 2024 | -67.32 Mn |
| Mar 31, 2024 | -55.33 Mn |
| Dec 31, 2023 | -52.01 Mn |
| Sep 30, 2023 | -44.71 Mn |
| Jun 30, 2023 | -49.22 Mn |
| Mar 31, 2023 | -38.16 Mn |
| Dec 31, 2022 | -42.72 Mn |
| Sep 30, 2022 | -40.91 Mn |
| Jun 30, 2022 | -29.23 Mn |
| Mar 31, 2022 | -30.04 Mn |
| Dec 31, 2021 | -32.01 Mn |
| Sep 30, 2021 | -26.62 Mn |
| Jun 30, 2021 | -29.56 Mn |